Investigational drug · Phase 3
Otaplimastat
Also called: SP-8203
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ischemic Stroke.
Phase 3Last checked: Nov 20, 2026Latest source record: Mar 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "Otaplimastat"
First trial start
2025
Feb 14, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Otaplimastat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Otaplimastat" as an intervention, largest first.
- Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of CarePivotal-lookingRecruiting
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT06660719 · 852 participants (planned) · Start Feb 14, 2025 · Primary completion Mar 30, 2027
Drug: SP-8203; Placebo · For: Ischemic Stroke
Sites: Busan, South Korea; Ulsan, South Korea
- Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPAPivotal-lookingCompleted
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT04479449 · 178 participants · Start Mar 18, 2019 · Primary completion Oct 19, 2020
Drug: SP-8203; Placebo · For: Ischemic Stroke
Sites: Seoul, South Korea
- Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPACompleted
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT02787278 · 80 participants · Start Jun 5, 2016 · Primary completion May 30, 2017
Drug: SP-8203 High dose; SP-8203 Low dose and 1 more · For: Ischemic Stroke
Sites: Busan, South Korea; Daegu, South Korea; Gyeonggi-do, South Korea · 8 sites in all
Shin Poong Pharmaceutical Co. Ltd.Industry
NCT01757795 · 72 participants · Start Dec 23, 2013 · Primary completion Mar 11, 2015
Drug: SP-8203; Placebo · For: Ischemic Stroke
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies.
Dammavalam V, Lin S, Nessa S, et al. · Int J Mol Sci 2024
- Neuroprotection for Nonarteritic Central Retinal Artery Occlusion: Lessons from Acute Ischemic Stroke.
Okonkwo ON, Agweye CT, Akanbi T · Clin Ophthalmol 2023
- The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia.
Song HY, Chung JI, Jalin AMA, et al. · Int J Mol Sci 2022
- The future of neuroprotection in stroke.
Chamorro Á, Lo EH, Renú A, et al. · J Neurol Neurosurg Psychiatry 2021
- Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
Kim JS, Lee KB, Park JH, et al. · Ann Neurol 2020
- Identification of new fluorophores in coelomic fluid of Eisenia andrei earthworms.
Kruk J, Dziurka M, Pytycz B · PLoS One 2019
Also in development for Ischemic Stroke
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- Umbilical Cord Mesenchymal Stem CellsMesenchymal stromal cells, Allogeneic Mesenchymal Stem CellsPhase 24 trials
PT. Prodia Stem Cell Indonesia · Diabetic Nephropathy Type 2, Ischemic Stroke, Cerebral Palsy
- TS23Phase 22 trials
Translational Sciences, Inc. · Ischemic Stroke, Pulmonary Embolism
- NCS-01Phase 21 trial
NC Medial Research Inc · Ischemic Stroke
- TBO-309Phase 21 trial
ThromBio Pty. Ltd. · Ischemic Stroke, Tandem Occlusion
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.